reports
- GlobalData Healthcare Department
MyoKardia Inc (MYOK) - Financial Analysis Review
MyoKardia Inc (MYOK) - Financial Analysis Review Summary MyoKardia Inc (MyoKardia) is a clinical stage biopharmaceutical company which discovers, develops and commercializes therapies for rare cardiovascular diseases. It primarily focuses on the treatment of heritable cardiomyopathies. The company’s pipeline portfolio includes MYK-461 is an orally administered small molecule which is designed to reduce left ventricular contractility by allosterically modulating the function of cardiac myosin...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.